Krystal Biotech (KRYS)
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
📈 **POSITIVE** • Low confidence analysis (54%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (84%) **Content type:** Clinical